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Abstract
MicroRNAs (miRNA) have emerged as an important new class of modulators of gene expression. In this study we
investigated miRNA that are differentially expressed in lupus nephritis. Microarray technology was used to investigate
differentially expressed miRNA in peripheral blood mononuclear cells (PBMCs) and Epstein-Barr Virus (EBV)-transformed cell
lines obtained from lupus nephritis affected patients and unaffected controls. TaqMan-based stem-loop real-time
polymerase chain reaction was used for validation. Microarray analysis of miRNA expressed in both African American (AA)
and European American (EA) derived lupus nephritis samples revealed 29 and 50 differentially expressed miRNA,
respectively, of 850 tested. There were 18 miRNA that were differentially expressed in both racial groups. When samples
from both racial groups and different specimen types were considered, there were 5 primary miRNA that were differentially
expressed. We have identified 5 miRNA; hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663
that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested. Hsa-miR-
371-5P, hsa-miR-1224-3P and hsa-miR-423-5P, are reported here for the first time to be associated with lupus nephritis. Our
work establishes EBV-transformed B cell lines as a useful model for the discovery of miRNA as biomarkers for SLE. Based on
these findings, we postulate that these differentially expressed miRNA may be potential novel biomarkers for SLE as well as
help elucidate pathogenic mechanisms of lupus nephritis. The investigation of miRNA profiles in SLE may lead to the
discovery and development of novel methods to diagnosis, treat and prevent SLE.
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Introduction
Systemic Lupus Erythematosus( S L E )i sac o m p l e xa u t o i m -
mune disease. The immunological hallmark of SLE is the
production of a range of autoantibodies directed at ubiquitous
nuclear components. It is characterized by immune-mediated
damage to multiple organ systems with a corresponding diverse
array of systemic symptoms. The etiology of SLE is still
undetermined, but it is known to involve a complex interaction
of genetic and environmental factors [1][2]. SLE has a
prevalence of ,40 cases per 100,000 individuals with onset
typically occurring in women of childbearing age (F:M ratio 9:1)
[3]. There is a diverse variation in disease prevalence in
different ethnic populations with a 3–4 times increased
prevalence in African American (AA) [3,4], and an elevated
rate of nephritis relative to European Americans (EA). AA lupus
has an earlier age of onset and a clinically more severe
phenotype [5]. Nephritis is often a severe manifestation of SLE
[6,7] and is frequently linked to a poor long-term prognosis with
a greater than four-fold increase in mortality [8].
Current aggressive immunosuppression therapies are effective in
controlling renal lupus flares and have improved disease outcomes,
but side effects such as infection, malignancy, metabolic
disturbances, and infertility make this treatment option unsatis-
factory. Potential contributions of microRNA to the pathogenesis
and mechanisms of damage to kidneys in SLE-associated nephritis
may allow development of more specific, effective, and less toxic
therapies. In addition, conventional immunosuppressive drugs for
treatment of SLE associated nephritis, such as corticosteroids,
cyclophosphamide, and azathioprine, could be used more
effectively and with fewer side effects if clinicians could accurately
predict SLE-associated nephritis or renal flare and response to
treatment [9]. The use of unique miRNA expression signatures
could be an important and cost-effective means to monitor
predisposition to lupus nephritis or its pathogenesis.
Small non-coding RNA molecules (microRNA or miRNA) are a
gene expression and protein synthesis modulating mechanism that
has been recently identified in several species including humans.
These miRNA are single-stranded RNA molecules of about 20–25
nucleotides (nt) encoded by nuclear genes (70–150 nt) and are
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into proteins but are processed from primary transcripts (called
pri-miRNA) to short stem-loop structures called pre-miRNA and
finally to functional miRNA. The expression pattern of miRNA
varies over time and between tissues. These mature miRNA
molecules are partially complementary to one or more mRNA
sequences and they function through sequence-specific down-
regulation of their target mRNA via mRNA degradation or
inhibition of translation [10]. In the public miRNA database
(miRBase) there are over 700 proposed human miRNA.
MiRNA are now recognized as one of the most highly abundant
agents of gene regulation at the post-transcriptional level in higher
eukaryotes [11,12]. It is estimated that miRNAs account for 1–5%
of expressed genes in the animal genome and about 20–30% of all
human mRNA are known to be miRNA targets. Because miRNA
function as managers in gene regulatory networks, they are distinct
from other biomarkers because they may have an upstream and
potentially pathogenic role in the disease process. Quantitation of
miRNA gene expression levels has become an essential step in
understanding mechanisms for cellular processes such as cell
differentiation, cell proliferation and cell death, and has shown
great promise in identifying effective biomarkers that correlate
with human diseases [13].
Although dysregulation of miRNA expression has been
characterized mostly in cancer, it has recently been studied in
many other diseases. Specifically, miRNA have been proposed as a
regulator of immune cell development [14], playing a role in the
inflammatory response [15] and as a key player in the
pathogenesis of neurodegenerative diseases [16]. The relationship
between SLE and miRNA was first reported by Dai et al who
studied the relationship in PBMCs [17] and renal biopsies [9]
obtained from Chinese SLE patients. The role miRNA play in
autoimmune diseases is incomplete or only beginning to be
characterized especially with regard to miRNA. However, the
importance of miRNA on post-transcriptional regulation of gene
expression in SLE is emerging with some surprising results. In one
relevant example a mouse model of SLE with defects in miRNA
regulation of mRNA induced disease. Here miRNA101 suppresses
expression of the ICOS (a costimilatory molecule on T cells),
which is defective in sanroque model of lupus, leading to
stimulation of autoreactive B cells and a lupus-like illness [18].
Understanding the role of miRNA in SLE may have important
implications for disease pathology.
We evaluated miRNA expression by microarray technology in
samples obtained from lupus nephritis patients and unaffected
controls. In these samples we identified changes in miRNA
expression that correlate with lupus. Five miRNA (hsa-miR-371-
5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-
miR-663) were differentially expressed across different racial
groups and in all specimen types tested. Three of these miRNA
(hsa-miR-371-5P, hsa-miR-1224-3P and hsa-miR-423-5P) were
associated with lupus nephritis and are reported here for the first
time. These miRNA may be potential novel biomarkers or may
help to elucidate pathogenic mechanisms of lupus nephritis.
Results
MiRNA expression profiles in EBV-transformed B-cell lines
derived from SLE African American samples
In the initial effort to use lupus study participants derived EBV-
transformed B-cell lines to identify differentially expressed miRNA
in lupus patients, we performed microarray analysis of miRNA
expression profiles in EBV-transformed cells from 10 AA SLE
patients with nephritis as well as from unaffected controls. Patients
were matched by gender, age and race.
We observed a total of 29 miRNAs that were differentially
expressed in SLE-affected patients compared to unaffected
controls (Table 1). Twenty four were up-regulated and 5 were
down-regulated in these SLE samples.
Validation of the miRNA expression
To validate microarray results, three miRNA—has-miR-148A,
has-miR-423-5P and has-miR-371-5P—were randomly selected for
quantitative real-time PCR (QRT-PCR) verification using stem-loop
r e a l - t i m eP C R .I nt h i ss t u d yan e ws e to fR N Ai s o l a t e df r o ma n o t h e r
culture of EBV-transformed B-cell lines was used as described in
Material and Methods. The RNA used in these experiments was
extracted at a different time from the EBV-transformed cell lines
obtained from 3 SLE patients and a control pool (2 unaffected
donors). The QRT-PCR results obtained here validated the
microarray data (data not shown) because the ratios (see Materials
and Method Section) in both experiments were very similar. For
example, the ratios of has-miR-148A, has-miR-423-5P and has-miR-
Table 1. MiRNAs differentially expressed in SLE African
American samples derived cell lines.
Differential
Expression Type MiRNA Name Mean Ratio
Up-regulated hsa-miR-886-3P 4.8761.43
hsa-miR-142-3P 2.8460.45
hsa-miR-23A 2.6260.89
hsa-miR-602 2.5160.71
hsa-miR-371-5P 2.4461.20
hsa-miR-125A-3P 2.3461.12
hsa-miR-720 2.3360.67
hsa-miR-148A 2.3260.66
hsa-miR-142-5P 2.2360.65
hsa-let-7I 2.2060.80
hsa-miR-27A 2.0960.45
hsa-miR-92B* 2.0960.35
hsa-miR-487B 2.0760.55
hsa-miR-26A 2.0260.04
hsa-miR-373* 2.0260.44
hsa-miR-181A 2.0161.27
hsa-miR-663 1.8660.25
hsa-miR-27B 1.8060.17
hsa-miR-23B 1.8060.28
hsa-miR-30C 1.8060.08
hsa-miR-191 1.7360.30
hsa-miR-638 1.6260.12
hsa-miR-24 1.5961.00
hsa-miR-423-5P 1.5361.29
Down-regulated hsa-miR-342-3P 0.6060.03
hsa-miR-328-5P 0.5160.15
hsa-miR-1224-3P 0.4860.06
hsa-miR-1228* 0.3860.10
hsa-miR-149* 0.3560.14
doi:10.1371/journal.pone.0010344.t001
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in QRT-PCR test they were 2.54, 1.63 and 2.72.
MiRNAs expression profile in PBMCs derived from SLE
African American samples
The hypothesis guiding our study is that a distinct profile of
miRNA expression alters gene expression to contribute to SLE,
and more specifically that this profile is evident in B cells and is
retained and faithfully represented in these transformed cell lines.
To investigate the authenticity of EBV-miRNAs association with
SLE, RNA extracted from frozen PBMCs obtained from the
LFRR of AA SLE-affected patients and unaffected matched
controls were used. In this study miRNA profiles were obtained by
comparing the pool of SLE patients (5 AA in the SLE pool) and
the pool of control (5 AA in the control pool) samples. The
individual RNA of appropriate samples was added into each pool
after RNA extraction.
As shown in Table 2, a total of 21 miRNA were differentially
expressed in the SLE-affected samples compared to the unaffected
matched controls. Twenty miRNA were up-regulated and one was
down-regulated. The study also revealed that the 6 miRNA; hsa-
miR-342-3P, hsa-miR-27B, hsa-miR-371-5P, hsa-miR-423-5P,
hsa-miR-638 and hsa-miR-663, were differentially expressed in
both experiments using EBV-transformed B-cell lines (Table 1)
and PBMCs. This indicates that EBV-transformed B-cell lines
derived from SLE-affected patients and unaffected controls can be
used to develop a miRNA signature associated with SLE. The use
of EBV-transformed B-cells in these types of studies has
advantages because the cell lines are assumed to be cultured in a
uniform environment independent of the consequences of the
disease and pathogenesis of SLE can be studied in a patient
population that may not be accessible or are no longer living.
MiRNAs expression profile in SLE European American
samples
The preceding experiments performed with AA samples estab-
lished the utility of the EBV-transformed B- cell lines obtained from
SLE-affected patients as suitable reagents for evaluating miRNA
association with lupus. Therefore, to extend the study to another
ancestry, we used EBV-transformed B-cell lines obtained from 10
SLE-affected patients and 10 matched unaffected controls to
investigate differential miRNA expression in EA.
A total of 50 miRNA (Table 3) were differentially expressed in
the EA SLE-affected samples compared to the unaffected matched
controls. Forty-two were up-regulated and 8 were down-regulated.
In this study 17 and 7 miRNA that were previously differentially
expressed in AA SLE derived B-cell lines and PBMCs,
respectively, (Tables 1 and 2) were also differentially expressed
in these EA samples. These results suggest that specific miRNAs
differentially expressed across racial groups may be SLE disease
specific.
MiRNAs expression profiles in SLE discordant identical
twins
The evidence for a strong genetic component to SLE comes
from the many genes shown to be associated with SLE as well as
the observations that SLE disease concordance rate is 24–58% for
monozygotic twins compared to 2–5% for dizygotic twins and
other siblings is a 10-fold difference [1]. To examine the miRNA
profile in AA SLE discordant identical twins, we used EBV-
transformed B-cell lines obtained from a SLE-affected twin and an
unaffected monozygotic twin as control. The SLE twin was both
anti-dsDNA and renal-disorder negative.
In this study a total of 31 miRNAs (Table 4) were differentially
expressed in SLE-affected twin compared to the unaffected
monozygotic twin controls. Twenty-nine were up-regulated and
2 were down-regulated. Of these, 9, 15 and 18 were previously
shown to be differentially expressed in PBMCs, AA cell lines and
EA cell lines, respectively.
Discussion
The experiments reported here were performed primarily using
EBV-transformed B cell lines obtained from SLE-affected patients
and unaffected controls. Our results suggest EBV-transformed B
cell lines are a useful reagent for discovery of miRNA as
biomarkers for SLE. The use of EBV-transformed B-cells in these
studies has several advantages; i) The Lupus Family Registry and
Repository (LFRR) at Oklahoma Medical Research Foundation
(OMRF) has a substantial number of EBV-transformed cell lines
obtained from SLE cases and controls, which are readily available
for study. ii) The cell lines are 100% B-cells and therefore
eliminate cell population variations. iii) The cells allow the
identification and characterization of B-cell specific miRNAs that
are associated with SLE. Therefore, the mechanism by which SLE
differentially-expressed miRNAs affects a subset of target genes
can be investigated by focusing on the pathway that leads to B-cell
activation.
Here, we investigated the association of miRNA with SLE.
Using miRNA microarray analysis, we isolated and analyzed
miRNA in EBV-transformed B-cell lines and frozen PMBCs
obtained from SLE-affected patients with nephritis as well as
unaffected controls. The study identified 5 miRNA—hsa-miR-
371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and
Table 2. MiRNAs differentially expressed in SLE African
American samples derived PBMCs.
Differential
Expression Type MiRNA Name Mean Ratio
Up-regulated hsa-miR-675 3.96
hsa-miR-199A-3P-199B-3P 3.34
hsa-miR-371-5P 2.80
hsa-miR-18A 2.74
hsa-miR-199A-5P 2.53
hsa-miR-150* 2.47
hsa-miR-185 2.33
hsa-miR-20B 2.13
hsa-miR-223 1.97
hsa-miR-663 1.94
hsa-miR-25 1.88
hsa-miR-423-3P 1.86
hsa-miR-93 1.79
hsa-miR-638 1.69
hsa-miR-301A 1.64
hsa-miR-27B 1.61
hsa-miR-361-3P 1.55
hsa-miR-92A 1.53
hsa-miR-155 1.53
hsa-miR-145 1.51
Down-regulated hsa-miR-342-3P 0.63
doi:10.1371/journal.pone.0010344.t002
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ancestries and all specimen types tested. The miRNA, hsa-miR-
371-5P, hsa-miR-1224-3P and hsa-miR-423-5P, are associated
with lupus nephritis and are reported here for the first time. The
other two miRNA we detected in this study, hsa-miR-638 and hsa-
miR-663, have previously been reported [9] to be associated with
lupus nephritis in Chinese renal biopsies samples. The three
miRNA—hsa-miR-181, hsa-miR-186, and hsa-miR-590-3p—
together predicted to target a number of lupus genes [19], only
Table 3. MiRNAs differentially expressed in SLE European
American samples derived cell lines.
Differential
Expression Type MiRNA Name Mean Ratio
Up-regulated hsa-miR-638 6.9061.33
hsa-miR-328-5P 6.4561.50
hsa-miR-1228* 5.8663.56
hsa-miR-663 5.3460.75
hsa-miR-92B* 5.0763.91
hsa-miR-371-5P 4.9261.20
hsa-miR-675 4.8862.00
hsa-miR-125A-3P 4.7162.56
hsa-miR-483-5P 4.6061.51
hsa-miR-665 4.4462.90
hsa-miR-602 4.3763.98
hsa-miR-187* 4.3362.75
hsa-miR-423-3P 4.2361.17
hsa-miR-583 4.0161.50
hsa-miR-654-5P 3.7361.98
hsa-miR-150* 3.6360.95
hsa-miR-933 3.5061.17
hsa-miR-149* 3.4761.54
hsa-miR-744 3.4061.29
hsa-miR-516A-5P 3.3160.65
hsa-miR-373* 3.2561.01
hsa-miR-550 3.1561.50
hsa-miR-92B 3.0560.91
hsa-miR-181A 3.0361.98
hsa-miR-320A 2.8261.47
hsa-miR-30C-1* 2.7860.90
hsa-miR-378 2.6960.86
hsa-miR-30B 2.6660.37
hsa-miR-30D 2.5960.89
hsa-miR-198 2.4260.46
hsa-miR-298 2.2960.18
hsa-miR-874 2.2860.67
hsa-miR-135A* 2.1460.64
hsa-miR-765 2.0360.57
hsa-miR-659 1.9860.53
hsa-miR-193B 1.9560.30
hsa-miR-494 1.8361.54
hsa-miR-222 1.7560.81
hsa-miR-142-3P 1.7461.45
hsa-miR-29C 1.6660.15
hsa-miR-140-3P 1.6160.68
hsa-miR-148A 1.6161.31
Down-regulated hsa-miR-20A 0.5860.07
hsa-miR-26A 0.5360.09
hsa-miR-768-3P 0.5060.11
hsa-miR-1224-3P 0.5060.10
hsa-miR-886-3P 0.4960.12
hsa-miR-720 0.4860.08
Differential
Expression Type MiRNA Name Mean Ratio
hsa-miR-155 0.4660.11
doi:10.1371/journal.pone.0010344.t003
Table 3. Cont.
Table 4. MiRNAs profile from monozygotic discordant twins.
Differential
Expression Type MiRNA Name Mean Ratio
Up-regulated hsa-miR-638 13.82
hsa-miR-149* 6.64
hsa-miR-1228* 5.48
hsa-miR-146A 5.05
hsa-miR-328-5P 4.86
hsa-miR-146B-5P 3.74
hsa-miR-423-3P 3.65
hsa-miR-34A 3.42
hsa-miR-29A 3.05
hsa-miR-675 2.94
hsa-miR-24 2.84
hsa-miR-663 2.84
hsa-miR-222 2.83
hsa-miR-371-5P 2.65
hsa-miR-21 2.47
hsa-miR-92B* 2.47
hsa-miR-221 2.37
hsa-miR-30D 2.09
hsa-miR-23A 2.01
hsa-miR-342-3P 2.00
hsa-Let-7I 1.93
hsa-Let-7G 1.92
hsa-miR-92A 1.85
hsa-miR-150* 1.83
hsa-Let-7C 1.80
hsa-miR-125A-3P 1.80
hsa-Let-7F 1.66
hsa-miR-483-3P 1.64
hsa-miR-373* 1.57
Down-regulated hsa-miR-720 0.50
hsa-miR-155 0.47
doi:10.1371/journal.pone.0010344.t004
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isolated from EBV-transformed B-cell lines obtained both AA and
EA SLE affected patients. The miRNA reported here may serve as
SLE-specific signature miRNA and could be used as a biomarker
for the diagnosis of at least lupus nephritis.
Lupus nephritis is severe and the available treatment regimens
are effective; however, because of the side effects, treatments are
associated with significant morbidity and mortality [9]. The
discovery and development of new biomarkers such as the miRNA
detected in this study of lupus nephritis could help in mitigating
the side effects of the treatments by predicting the onset, severity
and response of renal flares and thus allowing for the adjustment of
therapy with the disease stage.
Our miRNA microarray analysis also revealed additional 7
miRNA—hsa-miR-1228*, hsa-miR-125A-3P, hsa-miR-149*, hsa-
miR-328-5P, hsa-miR-373*, hsa-miR-720 and hsa-miR-92B*—
that were differentially expressed in cell lines but not in frozen
PBMC samples. This may be due to fact that the PMBC
experiment was done on pooled samples or due to a difference in
specimen types. The miRNA hsa-miR-342-3P was differentially
expressed in AA samples only. The 10 miRNA reported here have
also been reported elsewhere [9] further confirming the utility of
EBV-transformed cell lines. As has been reported in previous
studies [9] our study also did not reproduce most of the miRNA
profile reported by Tang et al. [20], In fact the primary miRNA,
has-miR-146a, they determined to be associated with lupus, was
only shown to be differentially expressed in discordant identical
twins microarray analysis. This could be attributable to differences
in the methodology used, and/or major SLE phenotype studied in
each case because the SLE identical twin was one of the two
patients that was negative for both renal-disorder and anti-dsDNA
(Table 5). This observation might be anticipated because SLE is a
complex disease and therefore, each major SLE phenotype might
have different miRNA profiles and from this study we can
speculate that has-miR-146a may be differentially expressed in
SLE patients who are negative for renal-disorder or anti-dsDNA
or both.
In the effort to explore the possible molecular mechanisms of
the regulation by the 5 major miRNA identified above, we used
bioinformatics prediction tools such as miRBase at http://www.
mirbase.org/to search for the potential molecular targets among
the genes that have been reported to associate with SLE
pathogenesis [21–25]. This bioinformatics investigation revealed
the potential gene targets for the primary miRNA identified in this
study (Table 6) and most of these genes products are important
mediators of IFN signaling. These encouraging and interesting
observations link these miRNA to multiple components in the IFN
pathway.
Because miRNAs function as managers in gene regulatory
networks, they may provide quantitative regulation of genes
instead of on and off switch signals; therefore, they can be
considered as molecules that optimize a cell’s response to external
stimuli [26]. The work we present here, taken together with studies
reported previously on Chinese patients with lupus [17] [20]
indicate that there is good reason to further investigate the
connections between specific miRNAs and lupus. We and others
have identified novel miRNA associated with lupus nephritis, and
these molecules are potentially important diagnostic biomarkers
and may be involved in the pathogenesis of lupus nephritis.
Materials and Methods
Ethics
The study we describe was approved by the OMRF
Institutional Review Board (IRB) and all samples were obtained
with the written informed consents of the subjects.
Study subjects
Samples for these studies were obtained from the SLE patients
and controls recruited by the Oklahoma Medical Research
Foundation (OMRF) Lupus Family Registry and Repository
(LFRR). The LFRR is a unique SLE research resource. The
repository contains blood products from SLE patients and
unaffected controls from across the United States, Canada, Puerto
Rico, and the US Virgin Islands. In addition, the permanent B-cell
lines have been established for most of the peripheral blood
lymphocytes from both SLE patients and healthy donors. Finally,
the LFRR also store frozen peripheral blood mononuclear cells
(PBMCs) obtained from some SLE patients and unaffected
controls. A total of 52 samples were used in this study. These
included 26 SLE affected and 26 unaffected controls. Of these, 32
were from African American (AA) and 20 from European
American (EA) racial groups. The 52 samples were made up of
42 Epstein-Barr virus (EBV)-transformed cell lines and 10 PBMCs.
All SLE patients fulfilled at least four out of 11 of the American
Table 5. Clinical features of the subjects in the study.
Characteristics
SLE Affected
Patients
(n=26)
Unaffected
Controls
(n=26)
Gender, no. Male/Female 1/25 1/25
Ethnicity, no. AA/EA 16/10 16/10
Year of birth, mean6SD 1962.31611.01 1962.85612.51
Age at sample, mean6SD 40.69611.10 39.73612.90
Age at onset, mean6SD 31.88611.25 NA
Anti-dsDNA, no. positive/negative 24/2 0/26
Renal Disorder, no. positive/negative 24/2 0/26
Proteinuria, no. positive/negative 24/2 0/26
Malar Rash, no. positive/negative 16/10 0/26
Discoid Rash, no. positive/negative 11/15 0/26
Photosensitivity, no. positive/negative 13/13 0/26
Oral Ulcer, no. positive/negative 12/14 0/26
Arthritis, no. positive/negative 26/0 0/26
Serositis, no. positive/negative 20/6 0/26
Neuro Disorder, no. positive/negative 5/21 0/26
Hemolytic Anemia, no. positive/negative 5/21 0/26
Medications (Steroids or/and others) 26/26 NA
doi:10.1371/journal.pone.0010344.t005
Table 6. The potential gene target for the primary
differentially expressed miRNA.
Major miRNA identified Potential molecular Targets
hsa-miR-371-5P IL32, IFIT3, IFIT2, FGR, IRF5, CD40, PTTG1
hsa-miR-423-5P SLC2A4, VGF, SOX12
hsa-miR-638 CD79B, LY6E, ZNF330
hsa-miR-663 IL32, IFI35, CENTA1, LY6E, ZNF330
hsa-miR-1224-3P GPDH, PMVK, BSG
doi:10.1371/journal.pone.0010344.t006
MiRNA Profile and SLE
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at least 24 of these patients met the ACR criteria for lupus
nephritis. These cases were in general being actively treated. All of
them had been given or were taking prednisone or a comparable
corticosteroid. Of the 26, hydroxychloroquine or cloroquine
(n=1) had been used in 16. Azathiaprine was used in 18,
cyslophos[phamied in 9 and one each for cyclosporine and
mycophenolate mofetil. Nonsteriodal anti-inflammatory drugs has
been used in 21 of the cases. We had no therapeutic history from
the controls. Additional clinical information on the participants is
given in Table 5.
Preparation of EBV-transformed B-cell lines
Epstein-Barr virus-transformed cell lines of the SLE patients
and controls were obtained from the LFRR. The permanent B-cell
lines were established by EBV transformation of peripheral blood
lymphocytes from both SLE patients and apparently healthy
donors as described elsewhere [28]. At the time of experiment, the
selected EBV-transformed B cell lines were thawed and after
overnight incubation at 37uC in a humid atmosphere with 5%
CO2, the culture media was transferred to 15 ml conical tubes and
centrifuged for 10 minutes at 3006g. The cell pellet resuspended
in fresh complete RPMI media in T-25 flasks and expanded. One
million subconfluent cells was transferred to 50 ml conical tubes
and centrifugation step above repeated. Cells were washed twice
with 5 ml 1X PBS and pellets were flash frozen in liquid nitrogen
for 20–30 seconds and stored at 280uC until they were used for
preparation of total RNA.
Preparation of Frozen PBMCs
PBMCs (stored in liquid nitrogen) were obtained from the
LFRR. Vials containing approximately one million cells were
thawed in a water bath at 37uC and transferred into 50 ml conical
tubes containing 10 ml of complete media previously warmed at
37uC. The 50 ml conical tubes were centrifuged for 10 minutes at
3006g and the supernatants decanted. The cells were washed
twice with 5 ml 1X PBS and the pellets flash frozen in liquid
nitrogen for 20–30 seconds followed by storage at 280uC until
isolation of total RNA.
miRNA isolation
Two to 10 micrograms of total RNA were isolated from cell
suspensions of approximately 10
6 EBV-transformed B cells from
individual cell lines using a Trizol-based (Tri ReagentH [Sigma-
Aldrich, #T9424] or TrizolH [Invitrogen, #15596-026]) ap-
proach. This method captures small miRNAs that are lost by
silica-based isolation methods.
Cells were centrifuged and cell pellets lysed in Trizol reagent
followed by processing according to the manufacturer’s protocol.
Briefly, the aqueous phase of the cell lysate for each cell line was
transferred to a fresh tube and 0.5 ml of isopropanol per ml of
Trizol reagent used in the cell preparation was added to
precipitate RNA. The samples were incubated at room temper-
ature for 5–10 minutes and then centrifuged at 12,0006g for 10
minutes at 4uC. The RNA precipitate formed a pellet on the side
and bottom of the tube. The supernatant was removed from each
tube and the RNA pellets washed by adding 1 ml of 75% ethanol
per ml of Trizol reagent used in the cell preparation; the tubes
were mixed by vortexing and then centrifuged at 7,5006g for 5
minutes at 4uC. RNA pellets were briefly dried by air-drying or
under vacuum. RNA pellets were then dissolved by adding
appropriate volume of formamide, water or 0.5% SDS solution.
To facilitate dissolution, the RNA samples were mixed by repeat
pipetting with micropipetting at 55–60uC for 10–15 minutes. The
concentration and quantity of RNA were measured by UV
absorbance at 260 and 280 nm (A260/280 ratio) and checked by
gel electrophoresis. RNA samples were quality checked via the
Agilent 2100 Bioanalyzer platform (Agilent Technologies). The
results of the Bioanalyzer run were visualized in a gel image and
an electropherogram. The yields were 8–15 mg and RNA Integrity
Number (RIN) was between 7.2 and 10. According to published
data, RNA with a RIN number .6 is of sufficient quality for gene
expression profiling experiments as well as miRNA microarray
experiments [29,30].
MiRNA microarray analysis
miRNAs were labeled using 2 mg of total RNA and an Exiqon
miRCURY
TM Labeling Kit (#208032) or Exiqon Power Labeling
kit (208032-A) according to manufacturer’s specifications. These
kits use total RNA and enrichment of small RNA is not necessary.
The miRNA analysis was performed at Miltenyi Biotec Inc using
miRXplore Microarray product (Miltenyi Biotec Inc; Auburn,
CA). The microarray kit contains gene-specific oligonucleotide
probes generated from 850 human, 584 mouse, 426 rat and 122
viral precursor miRNAs. MiRXplore Microarrays carry DNA
oligonucleotides with a reverse-complementary sequence of
mature miRNAs. RNA samples to be analyzed were directly
labeled. After fluorescent labeling of miRNAs, the sample was
hybridized to the miRXplore Microarray. The fluorescence signals
generated by hybridization of miRNAs to array complementary
DNAs were detected and quantified using an Agilent laser scanner
(Agilent Technologies).
The miRNA labeling by manufacturer’s protocol employed
monoreactive Cy5 dye (Amersham Pharmacia Biotech, LTD) for
dyeing. The fluorescently labeled samples were hybridized
overnight to topic defined PIQOR
TM miRXplore Microarrays
using the a-Hyb
TM Hybridization Station. In general, control
samples are labeled with Hy3 and experimental samples are
labeled with Hy5. The fluorescent probes were lyophilized,
resuspended in 15 ml of diethyl pyrocarbonate (DEPC) water
and 5 mlo f4 6 hybridization buffer, denatured by heating for 5
minutes at 70uC and then snap-cooled on ice for 15 minutes. The
fluorescent probes were hybridized for 20 hours at 42uCi na
rotating hybridization oven and 0.25–1 mg of total RNA was used
per labeling reaction per slide hybridization. After hybridization,
slides were washed and then scanned (Agilent Technologies).
Image and Data Analysis
Mean signal and mean local background intensities were
obtained for each spot of the microarray images using the
ImaGene software (Biodiscovery). Low-quality spots were flagged
and excluded from data analysis. Unflagged spots were analyzed
with the PIQOR
TM Analyzer software. The PIQOR Analyzer
allows automated data processing of the raw data text files derived
from the ImaGene software. This includes background subtraction
to obtain the net signal intensity, data normalization, and
calculation of the Hy5/Hy3 ratios for the species of interest. As
an additional quality filtering step, only spots/genes are used for
the calculation of the Hy5/Hy3 ratio. Signals that are equal to or
higher than the 50% percentile of the background signal intensities
is used to generate a double-log scatter plot.
MiRNA ratio calculation
The PIQOR
TM Analyzer calculates all normalized mean Hy5/
Hy3ratiosofthefourreplicatespergene.MiRNAsthatare.1.5-fold
up- or down-regulated represent putative candidate miRNAs and are
highlighted by green and red colors in the miRNA re-ratio list. Green
color indicates a,0.66-fold down-regulation, corresponding to a fold
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sample. Red color indicates a more than 1.5-fold induction of the
respective miRNA in comparison to the control.
The entire microarray data are MIAME compliant and the raw
data have been deposited in a MIAME compliant database (GEO)
and the accession number is GSE21384.
Quantitative real-time PCR verification of microarray
results
Quantitative reverse transcription-PCR (RT-PCR) assays were
performed using a TaqMan miRNA assay kit (Applied Biosystems,
Foster City, CA) for the mature miRNA. The miR-148A, miR-
423-5P and miR-371-5p were randomly selected miRNAs for this
assay. Reverse transcription (RT) was performed using TaqMan
MicroRNA RT kit (Applied Biosystems). In this reaction of mature
miRNA 2 ng/ml of total RNA, 16 target-specific stem-loop RT
primer, 3.33 U/ml reverse transcriptase, 0.25 U/ml RNase inhib-
itor, 0.25 mM dNTPs, and 16reaction buffer were run in a total
reaction volume of 15 ml and incubated at 16uC for 30 min, 42uC
for 30 min, and 85uC for 5 minutes in a thermocycler (Applied
Biosystems).
Real-time PCR was performed using an Applied Biosystems
7900HT Sequence Detection System in a 10-ml PCR mixture
containing 1.33 ml of RT product, 26 TaqMan Universal PCR
Master Mix, 0.2 mM TaqMan probe, 15 mM forward primer, and
0.7 mM reverse primer. Each SYBR Green reaction was
performed with 1.0 ml of template cDNA, 10 mL of SYBR Green
mixture, 1.5 mM primer, and water to adjust the final volume to
20 ml.
The forward primer sequences for selected miRNAs and U6
were purchased from Applied Biosystems and used for real-time
PCR validation. These primers are: miR-148A: 59-TCAGTG-
CACTACAGAACTTTGT-39, miR-423-5P: 59-TGAGGGGCA-
GAGAGCGAGACTTT-39 and miR-371-5p: 59 ACTCAAACT-
GTGGGGGCACT-39. All reactions were incubated in a 96-well
plate at 95uC for 10 minutes, followed by 40 cycles of 95uC for 15
seconds, and 60uC for 1 minute; all were performed in triplicate.
The U6 gene was used as a control to normalize differences in
total RNA levels in each sample. The relative amount of each
miRNA to U6 RNA was expressed using equation 2
2DDCt, where
DDCt=(C t miRNA2CtU 6 ). The value of each control sample was
set at 1 and was used to calculate the fold change in target genes.
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